
|Articles|August 15, 2008
Azelastine eye drops receive FDA approval
Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
Advertisement
Key Points
Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
The substance azelastine is an antihistamine, and the eye-drop formulation is approved for treatment of allergic conjunctivitis in adults and children.
Meda is conducting a broad development program for the substance, both as eye drops and nasal spray. The azelastine eye drops sample is one part of that development.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5




























